Skip to main content

Table 2 Comparison of the availability of the DM and CVD medicines between the public hospitals, private hospitals and pharmacies

From: Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study

Availability of the medicines in %

    

Medicines

Private hospitals (n = 23)

Public hospitals (n = 22)

Private pharmacy (n = 100)

P value

A: Medicines with a statistically significant difference between study sites

 ARBs

87.0

31.8

99.0

<0.001

 ARB-thiazide diuretics

78.3

27.3

96.0

<0.001

 Statins

87.0

18.2

98.0

<0.001

 Warfarin

65.2

18.2

74.8

<0.001

 Soluble insulin

100

81.8

58.6

<0.001

 Thiazide diuretics

82.6

95.5

97.0

0.025

 Spironolactone

91.3

68.2

90.9

0.012

 LMWH

47.8

9.1

33.3

0.018

 UFH

39.1

4.6

19.2

0.014

 Isosorbide mono nitrate

30.4

4.6

32.3

0.030

B: Medicines with no statistically significant difference between study sites

 Captopril

91.3

95.5

98.0

0.277

 CCB

95.7

100

100

0.071

 Beta blockers

95.6

100

97.0

0.650

 Anti platelet drugs

91.3

91.0

97.0

0.317

 Digoxin

91.3

81.2

82.3

0.579

 Pre mixed insulin

69.6

77.3

54.1

0.080

 Intermediate insulin

43.5

27.3

34.3

0.516

 Benzathine penicillin

91.3

100

83.8

0.097

 Loop duiretics

91.3

100

86.9

0.182

 Hydralazine

65.2

45.6

43.4

0.166

 OHA

100

100

100

1

  1. UFH Unfractionated heparin, LMWH Low molecular weight heparin, ARB Angiotensin II receptor blockers, ACEI Angiotensin converting enzyme inhibitors, CCB Calcium channel blockers, OHA Oral hypoglycaemic agents